In addition to navitoclax, a recent study has described a novel dual BCL-2/BCL-XL inhibitor AZD4320, which appears to be highly active in acute myeloid leukemia (AML) preclinical models with reduced thrombocytopenia [41]. This evidence concerns the gene BCL2 and acute myeloid leukemia.